Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer Patients

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical Pharmacokinetics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00003088-200746120-00005PMID 18027989
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Third consensus on medical treatment of metastatic breast cancer.

  2007cited by this paper
• Second consensus on medical treatment of metastatic breast cancer.

  2007cited by this paper
• High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy

  2006cited by this paper
• Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia

  2006cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin

  2005cited by this paper
• Population Pharmacokinetics of Cyclophosphamide and Its Metabolites 4-Hydroxycyclophosphamide, 2-Dechloroethylcyclophosphamide, and Phosphoramide Mustard in a High-Dose Combination With Thiotepa and Carboplatin

  2005cited by this paper
• Metabolism‐based cyclophosphamide dosing for hematopoietic cell transplant

  2005cited by this paper
• Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.

  2005cited by this paper
• Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients.

  2005cited by this paper
• Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma

  2005cited by this paper
• Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans

  2004cited by this paper
• Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry

  2004cited by this paper
• Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.

  2004cited by this paper
• Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

  2003cited by this paper
• The effect of age on the early disposition of doxorubicin

  2003cited by this paper
• Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.

  2002cited by this paper
• Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.

  2002cited by this paper
• Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.

  2002cited by this paper
• Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer.

  2002cited by this paper
• Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.

  2002cited by this paper
• Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes.

  2001cited by this paper
• Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats.

  2000cited by this paper
• Pharmacokinetics of cyclophosphamide (CP) and 4‐OH‐CP/aldophosphamide in systemic vasculitis

  2000cited by this paper
• Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study.

  2000cited by this paper
• Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

  1999cited by this paper
• Simultaneous determination of N,N',N"-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography.

  1998cited by this paper
• Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography.

  1998cited by this paper
• Doxorubicin pharmacokinetics: the effect of abnormal liver biochemistry tests

  1998cited by this paper
• Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.

  1997cited by this paper
• Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.

  1995cited by this paper
• Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans.

  1992cited by this paper
• Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response.

  1992cited by this paper
• Limited sampling models for doxorubicin pharmacokinetics.

  1991cited by this paper
• A limited sampling strategy for cyclophosphamide pharmacokinetics.

  1989cited by this paper
• Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.

  1984cited by this paper
• Clinical Pharmacokinetics of Cyclophosphamide

  1979cited by this paper

• Phase I Randomized, Placebo-Controlled, Cross-Over Dose-Finding Study of Coenzyme Q10 on Doxorubicin Pharmacokinetics during Breast Cancer Treatment

  2025cites this paper
• Inter-individual variability, differential tissue abundance, and sub-cellular localization of human aldo-keto reductases (AKRs) and hydroxy-steroid dehydrogenases (HSDs).

  2025cites this paper
• Influence of Polymorphisms in Pharmacokinetics-Related Genes on the Areas Under the Plasma Concentration-Time Curves of Doxorubicin and Doxorubicinol in Patients with Diffuse Large B-Cell Lymphoma Receiving CHOP Therapy

  2025cites this paper
• Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial

  2024cites this paper
• A Population Pharmacokinetic Study to Evaluate Doxorubicin Exposure Across All Age Groups

  2024cites this paper
• Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs

  2023cites this paper
• R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study

  2023cites this paper
• A global sensitivity analysis of a mechanistic model of neoadjuvant chemotherapy for triple negative breast cancer constrained by in vitro and in vivo imaging data

  2023cites this paper
• Predicting Chemotherapy Distribution into Breast Milk for Breastfeeding Women Using a Population Pharmacokinetic Approach

  2023cites this paper
• Identifying mechanisms driving the early response of triple negative breast cancer patients to neoadjuvant chemotherapy using a mechanistic model integrating in vitro and in vivo imaging data

  2022cites this paper
• Tolerance and Outcomes of Neoadjuvant Chemotherapy in Geriatric Breast Cancer Patients.

  2022cites this paper
• PET imaging of mitochondrial function in acute doxorubicin-induced cardiotoxicity: a proof-of-principle study

  2022cites this paper
• Population pharmacokinetics of doxorubicin: A systematic review

  2022cites this paper
• Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP)

  2021cites this paper
• Evaluation for pharmacokinetic exposure of cytotoxic anticancer drugs in elderly patients receiving (R-)CHOP therapy

  2021cites this paper
• Cardioprotective Effects of Oroxylum indicum Extract Against Doxorubicin and Cyclophosphamide-Induced Cardiotoxicity

  2021cites this paper
• Is there scope for better individualisation of anthracycline cancer chemotherapy?

  2020cites this paper
• Gamma Tocopherol Reduced Chemotherapeutic-Induced ROS in an Ovarian Granulosa Cell Line, But Not in Breast Cancer Cell Lines In Vitro

  2020cites this paper
• Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically‐based pharmacokinetic modeling

  2020cites this paper
• Phase I feasibility study of Magnetic Resonance guided High Intensity Focused Ultrasound-induced hyperthermia, Lyso-Thermosensitive Liposomal Doxorubicin and cyclophosphamide in de novo stage IV breast cancer patients: study protocol of the i-GO study

  2020cites this paper
• Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients

  2020cites this paper
• Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells

  2019cites this paper
• Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP

  2019cites this paper
• The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells

  2019cites this paper
• Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing

  2019cites this paper
• The role of carbonyl reductase 1 in drug discovery and development

  2017cites this paper
• Epigenetics in ovarian cancer.

  2017cites this paper
• Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer.

  2016cites this paper
• Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer

  2016cites this paper
• Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).

  2016cites this paper
• Mathematical models of breast and ovarian cancers

  2016cites this paper
• The Scientific Basis of Body Surface Area–Based Dosing

  2014cites this paper
• Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.

  2014cites this paper
• Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years

  2013cites this paper
• A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity

  2013cites this paper
• Predictive Biomarkers in Breast Cancer: Their Value in Neoadjuvant Chemotherapy

  2012cites this paper
• Farmacocinética poblacional de gemcitabina aplicada a la personalización de su dosificación en pacientes oncológicos

  2012cites this paper
• A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model

  2012cites this paper
• Target Concentration Intervention in Oncology: Where Are We At?

  2012cites this paper
• Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy

  2012cites this paper
• [Populational pharmacokinetics of doxorubicin applied to personalised its dosing in cancer patients].

  2012cites this paper
• EORTC-related new drug discovery and development activities: role of the Pharmacology and Molecular Mechanisms Group

  2012cites this paper
• Dose optimization and body size

  2011cites this paper
• PKPD and Disease Modeling: Concepts and Applications to Oncology

  2011cites this paper
• Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes.

  2010cites this paper
• Impact of the Physiological Effects of Aging on the Pharmacokinetics and Pharmacodynamics of Systemic Breast Cancer Treatment

  2010cites this paper
• Valid generic substitution of carboplatin for patients with gynecological cancer.

  2009cites this paper
• Population Pharmacokinetics of Cyclophosphamide and Metabolites in Children With Neuroblastoma: A Report From the Children's Oncology Group

  2009cites this paper
• Pharmacogenetics of Human Carbonyl Reductase 1 (CBR1) in Livers from Black and White Donors

  2009cites this paper
• Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study

  2009cites this paper